Closing Perspectives and Future Directions in Multiple Myeloma Care

EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma

EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

EP: 5.Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma

EP: 6.Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma

EP: 7.Bispecific Antibody Efficacy and Safety in Multiple Myeloma: Updates from ASH 2025

EP: 8.Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma

EP: 9.Exploring Combination Bispecific Strategies in Multiple Myeloma with Talquetamab and Teclistamab from RedirecTT-1 Trial

EP: 10.Opportunities for Earlier Initiation of Bispecific Therapies in Multiple Myeloma

EP: 11.Role of Antibody-Drug Conjugates in Multiple Myeloma

EP: 12.Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

EP: 13.Transitioning Multiple Myeloma Care from Academic to Community Settings

Now Viewing

EP: 14.Closing Perspectives and Future Directions in Multiple Myeloma Care

In this final episode, experts offer closing reflections on the rapid evolution of multiple myeloma treatment and the growing role of bispecific antibodies. Panelists emphasize that the field is moving toward earlier use of immunotherapies, improved sequencing strategies, and stronger integration between academic and community practices. They highlight how bispecifics, CAR T-cell therapy, and antibody drug conjugates continue to reshape expectations for response and survival, particularly as real world data confirm efficacy in broader patient populations. Experts underscore the need for ongoing education, streamlined operational approaches, and robust toxicity management to ensure safe expansion of these therapies. They also stress the importance of equitable access so that innovations benefit patients across diverse geographic and clinical settings. The conversation concludes with optimism that continued collaboration, thoughtful trial design, and real world evidence will drive progress toward more durable disease control in multiple myeloma.